Compare NICE Ltd (NICE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Recursion Pharmaceuticals Inc — how do they compare? NICE Ltd trades at $101.98 (market cap $5.99B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: NICE Ltd is far larger — about 3.4× Recursion Pharmaceuticals Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NICE | RXRX | |
|---|---|---|
Market Cap | $5.99B | $1.78B |
Sector | Technology | Health |
52-Week High | $153.44 | $6.79 |
52-Week Low | $83.15 | $2.84 |
Enterprise Value | $5.72B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $101.85, up 4.88% today, showing strong momentum after exceeding Q2 2026 earnings expectations with $2.70 EPS versus $2.63 expected. The company maintains solid fundamentals with 65.12% gross margins and 13.86% net income margin, while technical indicators show bullish momentum with key resistance at $103. Recent partnerships with RingCentral and ESG initiatives highlight strategic growth positioning.
The outlook remains positive with analyst consensus target of $115 suggesting 13% upside potential. Key risks include competitive pressures in customer engagement software and potential margin compression as revenue growth outpaces profit growth. Institutional ownership trends show mixed activity with some firms increasing positions while others trim holdings.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
